Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit

Infectious Diseases

Volumn 47, Issue 10, 2015, Pages 751-753

  Vardakas, Konstantinos Z ^a,b   Matthaiou, Dimitrios K ^c   Falagas, Matthew E ^a,b,f   Antypa, Elli ^d   Koteli, Asimoula ^e   Antoniadou, Eleni ^d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d Department of Pathology   (Greece)

^e General Hospital Agios Pavlos   (Greece)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CARBAPENEMASE; COLISTIN; TIGECYCLINE; CARBAPENEM DERIVATIVE; MINOCYCLINE;

AGAR DIFFUSION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CRITICALLY ILL PATIENT; DRUG MEGADOSE; EPSILOMETER TEST; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LETTER; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; AGED; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; KLEBSIELLA INFECTIONS; MALE; MICROBIOLOGY; MIDDLE AGED;

AGED; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MINOCYCLINE;

EID: 84962497973     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1049659     Document Type: Letter

References (9)

1. Balandin Moreno B, Fernandez Simon I, Pintado Garcia V, Sanchez Romero I, Isidoro Fernandez B, Romera Ortega MA, et al Tigecycline therapy for infections due to carbapenemaseproducing Klebsiella pneumoniae in critically ill patients Scand J Infect Dis 2014; 46: 175-80.
2. Vardakas K Z, Matthaiou D K, Falagas M E, Antypa E, Koteli A, Antoniadou E.Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit JInfect 2014 Nov 15 (Epub ahead of print).
3. Magiorakos A P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 2012; 18: 268-81.
4. Clinical and Laboratory Standards Institute Performance standards for antimicrobial testing: twentieth informational supplement, CLSI document M100-S20 CLSI; 2010.
5. FDA Tygacil (Tigecycline) for injection; 2009 Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021821s016lbl.pdf
6. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS Effectiveness and safety of high-dose tigecyclinecontaining regimens for the treatment of severe bacterial infections Int J Antimicrob Agents 2014; 44: 1-7.
7. Ramirez J, Dartois N, Gandjini H, Yan J L, Korth-Bradley J, McGovern PC Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-Acquired pneumonia Antimicrob Agents Chemother 2013; 57: 1756-62.
8. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, et al Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemaseproducing K.pneumoniae in intensive care unit Clin Infect Dis 2013; 56: 697-700.
9. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence Antimicrob Agents Chemother 2014; 58: 654-63.